Fewer than one in 10 individuals who could benefit from obesity jabs like Wegovy can access them, states the global health agency as it issues its first guidance on the medications.
Given more than one billion individuals worldwide currently living with obesity, it is advocating for increased and just access to this class of drugs.
According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the injections that can help people shift substantial weight, explains the body.
Skinny Jab Supply Crisis
Even in the current best projected scenario, the supply of such drugs could only cover about 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The guideline calls on governments and firms to expand availability, through approaches including voluntary licensing.
Exclusive production rights on semaglutide – the core component of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Obesity Injections Operate
The injections mimick a biological compound to delay gastric emptying, curb appetite and enhance satiety so users eat less.
People commonly start to lose weight in the initial weeks of starting on the weekly injections.
Studies suggests people may put most of the weight back on after a year of stopping the drug, when their usual food cravings come back.
Being above a healthy weight increases your chance for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
